Loading…
Reported covered position: Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: SANOFI US SERVICES INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; international taxation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MERCK & CO., INC. · Firm: CROSSROADS STRATEGIES, LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PROTON THERAPY CONSORTIUM via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Reimbursement issues related to proton therapy on behalf of the National Association for Proton Therapy (NAPT).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LATHAM & WATKINS LLP OBO PEDIATRIC ASSOCIATES via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Source: Senate LDA
| SANOFI US SERVICES INC |
| 14 |
| 2023–2026 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 14 | 2023–2026 |
| AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE | 13 | 2024–2026 |
| ALTRIA CLIENT SERVICES LLC | 12 | 2023–2026 |
| HALEON US HOLDINGS LLC | 12 | 2024–2026 |
| THE BOEING COMPANY | 12 | 2023–2026 |
| BRISTOL-MYERS SQUIBB | 11 | 2023–2025 |
| MARSH MCLENNAN | 10 | 2024–2026 |
| VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA AG | 10 | 2023–2025 |
| INDIVIOR INC. | 9 | 2023–2025 |
| NOVAVAX, INC. | 9 | 2023–2025 |
| 3M COMPANY | 8 | 2025–2026 |
| ADVOCATES FOR COMMUNITY HEALTH | 8 | 2024–2025 |
| FOUNTAIN HOUSE | 8 | 2023–2025 |
| ALABAMA INSTITUTE FOR DEAF AND BLIND | 7 | 2025–2026 |
| BROAD INSTITUTE | 7 | 2025–2026 |
| KLASKO IMMIGRATION LAW PARTNERS, LLP ON BEHALF OF INTEALTH | 7 | 2025–2026 |
| ALABAMA INSTITUTE FOR DEAF & BLIND | 6 | 2023–2024 |
| CENTERSTONE | 6 | 2025–2026 |
| COCA-COLA BOTTLING COMPANY UNITED, INC. | 6 | 2025–2026 |
| COHNREZNICK LLP | 6 | 2023–2024 |
| EPILEPSY FOUNDATION OF AMERICA | 6 | 2025–2026 |
| MADRIGAL PHARMACEUTICALS, INC. | 6 | 2025–2026 |
| MANHATTAN INSTITUTE FOR POLICY RESEARCH, INC. | 6 | 2023–2024 |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 6 | 2025–2026 |
| BIOBOT ANALYTICS, INC. | 5 | 2023–2024 |
| GINKGO BIOWORKS, INC. | 5 | 2025–2026 |
| ALKERMES, INC. | 4 | 2026 |
| ARTERA INC. | 4 | 2023 |
| BLINK HEALTH, INC. | 4 | 2026 |
| DENSEBREAST-INFO, INC. | 4 | 2024 |
| KAZMIRA LLC | 4 | 2023 |
| PROTON THERAPY CONSORTIUM | 4 | 2026 |
| RESEARCH!AMERICA | 4 | 2026 |
| SQUARE 407 LP | 4 | 2025–2026 |
| ACTION NOW INITIATIVE, LLC (ANI) | 3 | 2023 |
| APNIMED, INC. | 3 | 2025–2026 |
| HONE HEALTH | 3 | 2024 |
| KIDNEY CARE PARTNERS | 3 | 2026 |
| MARIUS PHARMACEUTICALS | 3 | 2024 |
| ARRAY TECHNOLOGIES, INC. | 2 | 2025 |
| COALITION FOR 1099-K FAIRNESS | 2 | 2025 |
| DATA CENTER COALITION | 2 | 2025 |
| EDF POWER SOLUTIONS DEVELOPMENT, INC. (FKA EDF RENEWABLES DEVELOPMENT, INC.) | 2 | 2025 |
| LATHAM & WATKINS LLP OBO PEDIATRIC ASSOCIATES | 2 | 2026 |
| MICRON TECHNOLOGY, INC. | 2 | 2025 |
| SOLV ENERGY, LLC | 2 | 2025 |
| STRATA CLEAN ENERGY, LLC | 2 | 2025 |
| LILLY USA, LLC | 1 | 2023 |
Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI, INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: 3M COMPANY · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation, international tax and third-party litigation funding provisions.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: 3M COMPANY · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation, international tax and third-party litigation funding provisions.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; orphan drug tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: 3M COMPANY · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation, international tax and third-party litigation funding provisions.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: SANOFI US SERVICES INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; international taxation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; orphan drug tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: EISAI, INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MERCK & CO., INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
National Plan for Epilepsy Act
Client: EPILEPSY FOUNDATION OF AMERICA · Firm: CROSSROADS STRATEGIES, LLC
Funding for epilepsy program research at CDC, NIH, DoD; S.494/H.R.1189, National Plan for Epilepsy Act; FY2027 Department of Defense Appropriations; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. Support coverage of and access to all epilepsy treatments. Support PBM reform.
National Plan for Epilepsy Act
Client: EPILEPSY FOUNDATION OF AMERICA · Firm: CROSSROADS STRATEGIES, LLC
Funding for epilepsy program research at CDC, NIH, DoD; S.494/H.R.1189, National Plan for Epilepsy Act; FY2027 Department of Defense Appropriations Act (H.R.9495); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Support coverage of and access to all epilepsy treatments. Support PBM reform.
National Plan for Epilepsy Act
Client: EPILEPSY FOUNDATION OF AMERICA · Firm: CROSSROADS STRATEGIES, LLC
Funding for epilepsy program research at CDC, NIH, DoD; S.494/H.R.1189, National Plan for Epilepsy Act; FY2027 Department of Defense Appropriations Act (H.R.9495); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Support coverage of and access to all epilepsy treatments. Support PBM reform.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CROSSROADS STRATEGIES, LLC
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CROSSROADS STRATEGIES, LLC
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CROSSROADS STRATEGIES, LLC
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CROSSROADS STRATEGIES, LLC
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CROSSROADS STRATEGIES, LLC
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: CROSSROADS STRATEGIES, LLC
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: CROSSROADS STRATEGIES, LLC
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: CROSSROADS STRATEGIES, LLC
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: CROSSROADS STRATEGIES, LLC
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
FAIR Act
Client: AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE · Firm: CROSSROADS STRATEGIES, LLC
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2027 National Defense Authorization Act.
FAIR Act
Client: AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE · Firm: CROSSROADS STRATEGIES, LLC
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 National Defense Authorization Act (H.R.8800/S.4784).
FAIR Act
Client: AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE · Firm: CROSSROADS STRATEGIES, LLC
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 National Defense Authorization Act (H.R.8800/S.4784).
Community TEAMS Act of 2025
Client: AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE · Firm: CROSSROADS STRATEGIES, LLC
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 National Defense Authorization Act (H.R.8800/S.4784).
Community TEAMS Act of 2025
Client: AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE · Firm: CROSSROADS STRATEGIES, LLC
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 National Defense Authorization Act (H.R.8800/S.4784).
Community TEAMS Act of 2025
Client: AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE · Firm: CROSSROADS STRATEGIES, LLC
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2027 National Defense Authorization Act.
Department of Homeland Security Appropriations Act, 2026
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2026 Department of Homeland Security Appropriations Act (H.R.4213); FY2026 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.5342/S.2354); H.R.6938, Making consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-74); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2027 Department of Homeland Security Appropriations; FY2027 Commerce, Justice, Science, and Related Agencies Appropriations; FY2027 Financial Services and General Government Appropriations; FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations; FY2027 National Security, Department of State, and Related Programs Appropriations; provisions related to the regulation of tobacco products.
Financial Services and General Government Appropriations Act, 2026
Client: HALEON US HOLDINGS LLC · Firm: CROSSROADS STRATEGIES, LLC
Policies impacting access to over-the-counter products; FY2026 Financial Services and General Government Appropriations Act process (H.R.5166/S.3290); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ALABAMA INSTITUTE FOR DEAF AND BLIND · Firm: CROSSROADS STRATEGIES, LLC
Education funding and labor issues related to the disabled; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: LIFESCIENCE LOGISTICS · Firm: CROSSROADS STRATEGIES, LLC
Issues related to pandemic preparedness and strategic stockpile readiness, including funding for state strategic stockpiles demonstration included in the PREVENT Act; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: SQUARE 407 LP · Firm: CROSSROADS STRATEGIES, LLC
Issues related to the rescissions package; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); FY2026 Continuing Appropriations and Extensions Act (H.R.5371/P.L.119-37).
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2026 Department of Homeland Security Appropriations Act (H.R.4213); FY2026 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.5342/S.2354); H.R.6938, Making consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-74); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2027 Department of Homeland Security Appropriations; FY2027 Commerce, Justice, Science, and Related Agencies Appropriations; FY2027 Financial Services and General Government Appropriations; FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations; FY2027 National Security, Department of State, and Related Programs Appropriations; provisions related to the regulation of tobacco products.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: CROSSROADS STRATEGIES, LLC
General education to advance policies that support innovation in the medical device industry. Issues related to coverage and reimbursement of diagnostic tests, including Issues related to FDA regulation of medical devices. Issues related to medical device sterilization. Policy issues related to the regulation of artificial intelligence for medical technology. Policies that could impact supply chain for medical technology. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: CROSSROADS STRATEGIES, LLC
General education to advance policies that support innovation in the medical device industry. Issues related to the coverage and reimbursement of medical devices and technology, including AI. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: CROSSROADS STRATEGIES, LLC
General education to advance policies that support innovation in the medical device industry. Issues related to coverage and reimbursement of diagnostic tests, including issues related to FDA regulation of medical devices. Issues related to medical device sterilization. Policy issues related to the regulation of artificial intelligence for medical technology. Issues related to cybersecurity of medical devices manufactured in China. Policies that could impact supply chain for medical technology. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: CROSSROADS STRATEGIES, LLC
General education to advance policies that support innovation in the medical device industry. Issues related to coverage and reimbursement of diagnostic tests, including issues related to FDA regulation of medical devices. Issues related to medical device sterilization. Policy issues related to the regulation of artificial intelligence for medical technology. Issues related to cybersecurity of medical devices manufactured in China. Policies that could impact supply chain for medical technology. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: CROSSROADS STRATEGIES, LLC
General education to advance policies that support innovation in the medical device industry. Issues related to the coverage and reimbursement of medical devices and technology, including AI. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: CROSSROADS STRATEGIES, LLC
General education to advance policies that support innovation in the medical device industry. Issues related to the coverage and reimbursement of medical devices and technology, including AI. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: SQUARE 407 LP · Firm: CROSSROADS STRATEGIES, LLC
Issues related to the rescissions package; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); FY2026 Continuing Appropriations and Extensions Act (H.R.5371/P.L.119-37).
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); drug pricing; H.R.6130, Alzheimers Screening and Prevention (ASAP) Act of 2025.
Kidney Care Access Protection Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment, expand innovation, and other insurance/payment policies. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Kidney Care Access Protection Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment and expand innovation. Modernize Medicares payment system for end-stage renal disease (ESRD). Medicare coverage and reimbursement related to dialysis. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750). Improving Home Dialysis Act of 2026 (H.R.8875).
Kidney Care Access Protection Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment and expand innovation. Modernize Medicares payment system for end-stage renal disease (ESRD). Medicare coverage and reimbursement related to dialysis. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750). Improving Home Dialysis Act of 2026 (H.R.8875).
Kidney Care Access Protection Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment, expand innovation, and other insurance/payment policies. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Kidney Care Access Protection Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment and expand innovation. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Kidney Care Access Protection Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment and expand innovation. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2026 Department of Homeland Security Appropriations Act (H.R.4213); FY2026 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.5342/S.2354); H.R.6938, Making consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-74); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2027 Department of Homeland Security Appropriations; FY2027 Commerce, Justice, Science, and Related Agencies Appropriations; FY2027 Financial Services and General Government Appropriations; FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations; FY2027 National Security, Department of State, and Related Programs Appropriations; provisions related to the regulation of tobacco products.
Consolidated Appropriations Act, 2026
Client: ALABAMA INSTITUTE FOR DEAF AND BLIND · Firm: CROSSROADS STRATEGIES, LLC
Education funding and labor issues related to the disabled; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Consolidated Appropriations Act, 2026
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: CROSSROADS STRATEGIES, LLC
Discussions regarding implementation of medtech related provisions for FY26 and FY27; H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Consolidated Appropriations Act, 2026
Client: LIFESCIENCE LOGISTICS · Firm: CROSSROADS STRATEGIES, LLC
Issues related to pandemic preparedness and strategic stockpile readiness, including funding for state strategic stockpiles demonstration included in the PREVENT Act; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Consolidated Appropriations Act, 2026
Client: HALEON US HOLDINGS LLC · Firm: CROSSROADS STRATEGIES, LLC
Policies impacting access to over-the-counter products; FY2026 Financial Services and General Government Appropriations Act process (H.R.5166/S.3290); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75).
Consolidated Appropriations Act, 2026
Client: BROAD INSTITUTE · Firm: CROSSROADS STRATEGIES, LLC
General education about biomedical research and support for scientific funding. Transparency of federal funding for medical research dollars, including indirect costs. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75) and FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act and FY2027 Department of Defense Appropriations.
Farm, Food, and National Security Act of 2026
Client: COCA-COLA BOTTLING COMPANY UNITED, INC. · Firm: CROSSROADS STRATEGIES, LLC
Legislative and regulatory issues impacting the beverage industry, including SNAP in H.R.7567, Farm, Food, and National Security Act of 2026, and dietary guidelines. Issues related to the Make America Healthy Again Commission.
Farm, Food, and National Security Act of 2026
Client: COCA-COLA BOTTLING COMPANY UNITED, INC. · Firm: CROSSROADS STRATEGIES, LLC
Legislative and regulatory issues impacting the beverage industry, including SNAP and dietary guidelines; H.R.7567, Farm, Food, and National Security Act of 2026; S.5526, Agricultural Act of 2026; FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646). Issues related to the Make America Healthy Again Commission.
Farm, Food, and National Security Act of 2026
Client: COCA-COLA BOTTLING COMPANY UNITED, INC. · Firm: CROSSROADS STRATEGIES, LLC
Legislative and regulatory issues impacting the beverage industry, including SNAP and dietary guidelines; H.R.7567, Farm, Food, and National Security Act of 2026; FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646). Issues related to the Make America Healthy Again Commission.
Financial Services and General Government Appropriations Act, 2027
Client: HALEON US HOLDINGS LLC · Firm: CROSSROADS STRATEGIES, LLC
Policies impacting access to over-the-counter products; FY2027 Financial Services and General Government Appropriations Act (H.R.8495).
Financial Services and General Government Appropriations Act, 2027
Client: HALEON US HOLDINGS LLC · Firm: CROSSROADS STRATEGIES, LLC
Policies impacting access to over-the-counter products; FY2027 Financial Services and General Government Appropriations Act (H.R.8495).
Financial Services and General Government Appropriations Act, 2027
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Financial Services and General Government Appropriations Act, 2027
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Congressional Gold Medal For Inspiring Great Heroism and Tenacity (FIGHT) Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment and expand innovation. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Congressional Gold Medal For Inspiring Great Heroism and Tenacity (FIGHT) Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment, expand innovation, and other insurance/payment policies. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Congressional Gold Medal For Inspiring Great Heroism and Tenacity (FIGHT) Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment and expand innovation. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Congressional Gold Medal For Inspiring Great Heroism and Tenacity (FIGHT) Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment and expand innovation. Modernize Medicares payment system for end-stage renal disease (ESRD). Medicare coverage and reimbursement related to dialysis. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750). Improving Home Dialysis Act of 2026 (H.R.8875).
Congressional Gold Medal For Inspiring Great Heroism and Tenacity (FIGHT) Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment, expand innovation, and other insurance/payment policies. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Congressional Gold Medal For Inspiring Great Heroism and Tenacity (FIGHT) Act
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment and expand innovation. Modernize Medicares payment system for end-stage renal disease (ESRD). Medicare coverage and reimbursement related to dialysis. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750). Improving Home Dialysis Act of 2026 (H.R.8875).
Making appropriations for national security, Department of State, and related programs for the fiscal year ending September 30, 2027, and for other purposes.
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Making appropriations for national security, Department of State, and related programs for the fiscal year ending September 30, 2027, and for other purposes.
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: COCA-COLA BOTTLING COMPANY UNITED, INC. · Firm: CROSSROADS STRATEGIES, LLC
Legislative and regulatory issues impacting the beverage industry, including SNAP and dietary guidelines; H.R.7567, Farm, Food, and National Security Act of 2026; FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646). Issues related to the Make America Healthy Again Commission.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: CROSSROADS STRATEGIES, LLC
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); S.2658, Medication Affordability and Patent Integrity Act; S.3014, Ensuring Timely Access to Generics Act of 2025.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: CROSSROADS STRATEGIES, LLC
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); S.2658, Medication Affordability and Patent Integrity Act; S.3014, Ensuring Timely Access to Generics Act of 2025.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: COCA-COLA BOTTLING COMPANY UNITED, INC. · Firm: CROSSROADS STRATEGIES, LLC
Legislative and regulatory issues impacting the beverage industry, including SNAP and dietary guidelines; H.R.7567, Farm, Food, and National Security Act of 2026; S.5526, Agricultural Act of 2026; FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646). Issues related to the Make America Healthy Again Commission.
National Defense Authorization Act for Fiscal Year 2027
Client: SANOFI US SERVICES INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
National Defense Authorization Act for Fiscal Year 2027
Client: BROAD INSTITUTE · Firm: CROSSROADS STRATEGIES, LLC
Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495). Education and discussion regarding Broad Institute capabilities and technologies relevant to national biological intelligence, biosurveillance, and reconnaissance (ISR).
National Defense Authorization Act for Fiscal Year 2027
Client: EISAI, INC. · Firm: CROSSROADS STRATEGIES, LLC
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act (H.R.8800/S.4784); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
National Defense Authorization Act for Fiscal Year 2027
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: CROSSROADS STRATEGIES, LLC
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); S.2658, Medication Affordability and Patent Integrity Act; S.3014, Ensuring Timely Access to Generics Act of 2025.
National Defense Authorization Act for Fiscal Year 2027
Client: AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE · Firm: CROSSROADS STRATEGIES, LLC
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 National Defense Authorization Act (H.R.8800/S.4784).
National Defense Authorization Act for Fiscal Year 2027
Client: MERCK & CO., INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
National Defense Authorization Act for Fiscal Year 2027
Client: MERCK & CO., INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
National Defense Authorization Act for Fiscal Year 2027
Client: EISAI, INC. · Firm: CROSSROADS STRATEGIES, LLC
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act (H.R.8800/S.4784); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
National Defense Authorization Act for Fiscal Year 2027
Client: AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE · Firm: CROSSROADS STRATEGIES, LLC
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 National Defense Authorization Act (H.R.8800/S.4784).
National Defense Authorization Act for Fiscal Year 2027
Client: BROAD INSTITUTE · Firm: CROSSROADS STRATEGIES, LLC
Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495). Education and discussion regarding Broad Institute capabilities and technologies relevant to national biological intelligence, biosurveillance, and reconnaissance (ISR).
National Defense Authorization Act for Fiscal Year 2027
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: CROSSROADS STRATEGIES, LLC
Policies impacting third party repair of medtech. Issues related to competitive bidding in the FY2027 National Defense Authorization Act (H.R.8800/S.4784).
National Defense Authorization Act for Fiscal Year 2027
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: CROSSROADS STRATEGIES, LLC
Policies impacting third party repair of medtech. Issues related to competitive bidding in the FY2027 National Defense Authorization Act (H.R.8800/S.4784).
National Defense Authorization Act for Fiscal Year 2027
Client: BROAD INSTITUTE · Firm: CROSSROADS STRATEGIES, LLC
General education about biomedical research and support for scientific funding. Transparency of federal funding for medical research dollars, including indirect costs. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. Support for the NIH All of Us Program. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495).
National Defense Authorization Act for Fiscal Year 2027
Client: BROAD INSTITUTE · Firm: CROSSROADS STRATEGIES, LLC
General education about biomedical research and support for scientific funding. Transparency of federal funding for medical research dollars, including indirect costs. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. Support for the NIH All of Us Program. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495).
National Defense Authorization Act for Fiscal Year 2027
Client: GINKGO BIOWORKS, INC. · Firm: CROSSROADS STRATEGIES, LLC
Education and outreach on automated lab technology; FY2027 National Defense Authorization Act (H.R.8800/S.4784).
National Defense Authorization Act for Fiscal Year 2027
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: CROSSROADS STRATEGIES, LLC
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); S.2658, Medication Affordability and Patent Integrity Act; S.3014, Ensuring Timely Access to Generics Act of 2025.
National Defense Authorization Act for Fiscal Year 2027
Client: GINKGO BIOWORKS, INC. · Firm: CROSSROADS STRATEGIES, LLC
Education and outreach on automated lab technology; FY2027 National Defense Authorization Act (H.R.8800/S.4784).
National Defense Authorization Act for Fiscal Year 2027
Client: SANOFI US SERVICES INC. · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Improving Home Dialysis Act of 2026
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment and expand innovation. Modernize Medicares payment system for end-stage renal disease (ESRD). Medicare coverage and reimbursement related to dialysis. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750). Improving Home Dialysis Act of 2026 (H.R.8875).
Improving Home Dialysis Act of 2026
Client: KIDNEY CARE PARTNERS · Firm: CROSSROADS STRATEGIES, LLC
Education about how to improve the quality of kidney care treatment and expand innovation. Modernize Medicares payment system for end-stage renal disease (ESRD). Medicare coverage and reimbursement related to dialysis. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750). Improving Home Dialysis Act of 2026 (H.R.8875).
Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2027
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2027
Client: ALTRIA CLIENT SERVICES LLC · Firm: CROSSROADS STRATEGIES, LLC
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Issues related to Medicaid rate-setting for pediatric care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BROAD INSTITUTE via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
General education about biomedical research and support for scientific funding. Transparency of federal funding for medical research dollars, including indirect costs. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. Support for the NIH All of Us Program. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495).
General education about biomedical research and support for scientific funding. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. Education and awareness regarding genetic medicines for rare and ultra-rare diseases.
Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495). Education and discussion regarding Broad Institute capabilities and technologies relevant to national biological intelligence, biosurveillance, and reconnaissance (ISR).
General education about biomedical research and support for scientific funding. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. Federal policies related to OMB Uniform Guidance and their implications for federally funded biomedical research and research institutions. Federal science and technology policy, including OSTP priorities related to the future of federally supported research, scientific institutions, and national research capabilities.
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE
3M COMPANY via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Workforce, PPE, and industrial safety issues
EPA/environmental regulations. Issues related to PFAS.
Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation, international tax and third-party litigation funding provisions.
Trade issues related to Mexico.
Filing targets: Defense Advanced Research Projects Agency (DARPA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, U.S. Trade Representative (USTR)
SANOFI US SERVICES INC. via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to tax reform; international taxation.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); issues related to COPD and Type One Diabetes (T1D).
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL MULTIPLE SCLEROSIS SOCIETY via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
DoD funding-Congressionally Directed MS Research Program. NIH funding, FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Ensuring access to care and coverage for people living with multiple sclerosis. Healthcare research, FY2027 Department of Defense Appropriations Act (H.R.9495).
Supporting extension of Enhanced Advanced Premium Tax Credits.
Supporting established funding levels for Medicare and Medicaid and protection of Medicaid's financing structure.
MARSH MCLENNAN via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to health care reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
MADRIGAL PHARMACEUTICALS, INC. via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); GENEROUS Medicaid Drug Pricing Model.
Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Section 301 tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
LIFESCIENCE LOGISTICS via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to pandemic preparedness and strategic stockpile readiness.
Issues related to medical countermeasure and supply management.
Issues related to pandemic preparedness and strategic stockpile readiness, including state strategic stockpiles demonstration included in the PREVENT Act. Pandemic and All- Hazards Preparedness Act reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
HALEON US HOLDINGS LLC via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Education about the importance of OTC products and benefits under Medicare Advantage.
Issues related to healthcare and payment for over-the-counter drugs; General education of over-the-counter switches, including reauthorization of the Over-the-Counter Monograph Drug User Fee Act and policies impacting a Nonprescription Drug Product with an Additional Condition for Nonprescription Use.
Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.
GINKGO BIOWORKS, INC. via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Education and outreach on automated lab technology; FY2027 National Defense Authorization Act (H.R.8800/S.4784).
Filing targets: Agriculture, Dept of (USDA), Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COCA-COLA BOTTLING COMPANY UNITED, INC. via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Tariff issues related to aluminum.
Legislative and regulatory issues impacting the beverage industry, including SNAP and dietary guidelines; H.R.7567, Farm, Food, and National Security Act of 2026; S.5526, Agricultural Act of 2026; FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646). Issues related to the Make America Healthy Again Commission.
Legislative and regulatory issues impacting the beverage industry, including beverage labeling.
EPILEPSY FOUNDATION OF AMERICA via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Support affordable access to health insurance including through extension of Enhanced Advanced Premium Tax Credits.
Funding for epilepsy program research at CDC, NIH, DoD; S.494/H.R.1189, National Plan for Epilepsy Act; FY2027 Department of Defense Appropriations Act (H.R.9495); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Support coverage of and access to all epilepsy treatments. Support PBM reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTERSTONE via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Issues and funding related to community mental health and substance use disorder.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Housing & Urban Development, Dept of (HUD), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
BLINK HEALTH, INC. via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to market-based solutions to drug pricing, branded medication affordability, and patient access.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 National Defense Authorization Act (H.R.8800/S.4784).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
ALTRIA CLIENT SERVICES LLC via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Discussions related to FDA Tobacco and Cannabis Product Enforcement Policy.
Discussions regarding the taxation of tobacco products.
Issues related to the regulation of tobacco products. Issues related to FDA illicit product enforcement.
ALKERMES, INC. via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Policiesimpacting pharmaceutical development, patient access, drug pricing, and supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALABAMA INSTITUTE FOR DEAF AND BLIND via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Education funding and labor issues related to the disabled; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
General education to advance policies that support innovation in the medical device industry. Issues related to the coverage and reimbursement of medical devices and technology, including AI. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Policies impacting the supply chain and manufacturing of medical devices and technology including tariffs.
Policies impacting third party repair of medtech. Issues related to competitive bidding in the FY2027 National Defense Authorization Act (H.R.8800/S.4784).
VERTEX PHARMACEUTICALS INCORPORATED via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
THE BOEING COMPANY via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to reauthorization of the Toxic Substances Control Act.
Filing targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to tax reform; international taxation.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
RESEARCH!AMERICA via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Support for funding of research and policy issues related to indirect costs and accessibilityof grants and contracts. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Proposed Rule: Regulation for Federal Financial Assistance (Docket No. OMB-2026-0034; RIN 0348-AB88).
General education about the importance of support for federal funding of scientific research.
General educationand support for federal funding of medical research.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals; Section 301 tariffs.
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); S.2658, Medication Affordability and Patent Integrity Act; S.3014, Ensuring Timely Access to Generics Act of 2025.
MERCK & CO., INC. via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
KLASKO IMMIGRATION LAW PARTNERS, LLP ON BEHALF OF INTEALTH via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties.
Education about the impact of J-1 visa interview pause and travel ban impact for foreign physicians. Issues related to the proposed rule regarding establishing a fixed time period of admission and an extension of stay procedure for nonimmigrant academic students, exchange visitors, and representatives of foreign information media.
General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties. Education about the impact of J-1 visa interview pause and travel ban for foreign physicians. Issues related to the proposed rule regarding establishing a fixed time period of admission and an extension of stay procedure for nonimmigrant academic students, exchange visitors, and representatives of foreign information media.
KIDNEY CARE PARTNERS via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
Education about how to improve the quality of kidney care treatment, expand innovation, and other insurance/payment policies. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Education about how to improve the quality of kidney care treatment and expand innovation. Modernize Medicares payment system for end-stage renal disease (ESRD). Medicare coverage and reimbursement related to dialysis. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750). Improving Home Dialysis Act of 2026 (H.R.8875).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · Q3
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); drug pricing; H.R.6130, Alzheimers Screening and Prevention (ASAP) Act of 2025.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act (H.R.8800/S.4784); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
LATHAM & WATKINS LLP OBO PEDIATRIC ASSOCIATES via CROSSROADS STRATEGIES, LLC
2026 · third_quarter · RR
Issues related to Medicaid rate-setting for pediatric care.
3M COMPANY via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Workforce, PPE, and industrial safety issues
Trade issues related to Mexico.
Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation, international tax and third-party litigation funding provisions.
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
General education to advance policies that support innovation in the medical device industry. Issues related to coverage and reimbursement of diagnostic tests, including issues related to FDA regulation of medical devices. Issues related to medical device sterilization. Policy issues related to the regulation of artificial intelligence for medical technology. Issues related to cybersecurity of medical devices manufactured in China. Policies that could impact supply chain for medical technology. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Policies impacting third party repair of medtech. Issues related to competitive bidding in the FY2027 National Defense Authorization Act (H.R.8800/S.4784).
SANOFI US SERVICES INC. via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); issues related to COPD and Type One Diabetes (T1D).
Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
PROTON THERAPY CONSORTIUM via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Reimbursement issues related to proton therapy.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
NATIONAL MULTIPLE SCLEROSIS SOCIETY via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
DoD funding-Congressionally Directed MS Research Program. NIH funding, FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Ensuring access to care and coverage for people living with multiple sclerosis. Healthcare research, FY2027 Department of Defense Appropriations Act (H.R.9495).
Supporting established funding levels for Medicare and Medicaid and protection of Medicaid's financing structure.
Supporting extension of Enhanced Advanced Premium Tax Credits.
MARSH MCLENNAN via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to health care reform.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
MADRIGAL PHARMACEUTICALS, INC. via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Section 301 tariffs.
Issues related to CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
LIFESCIENCE LOGISTICS via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to pandemic preparedness and strategic stockpile readiness.
Issues related to medical countermeasure and supply management.
Issues related to pandemic preparedness and strategic stockpile readiness, including state strategic stockpiles demonstration included in the PREVENT Act. Pandemic and All- Hazards Preparedness Act reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HALEON US HOLDINGS LLC via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Education about the importance of OTC products and benefits under Medicare Advantage.
Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.
Policies impacting access to over-the-counter products; FY2027 Financial Services and General Government Appropriations Act (H.R.8495).
GINKGO BIOWORKS, INC. via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Education and outreach on automated lab technology; FY2027 National Defense Authorization Act (H.R.8800/S.4784).
Filing targets: Agriculture, Dept of (USDA), Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EPILEPSY FOUNDATION OF AMERICA via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Funding for epilepsy program research at CDC, NIH, DoD; S.494/H.R.1189, National Plan for Epilepsy Act; FY2027 Department of Defense Appropriations Act (H.R.9495); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Support coverage of and access to all epilepsy treatments. Support PBM reform.
Support affordable access to health insurance including through extension of Enhanced Advanced Premium Tax Credits.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COCA-COLA BOTTLING COMPANY UNITED, INC. via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Legislative and regulatory issues impacting the beverage industry, including SNAP and dietary guidelines; H.R.7567, Farm, Food, and National Security Act of 2026; FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646). Issues related to the Make America Healthy Again Commission.
Legislative and regulatory issues impacting the beverage industry, including beverage labeling.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
CENTERSTONE via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues and funding related to community mental health and substance use disorder.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Housing & Urban Development, Dept of (HUD), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals; Section 301 tariffs.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
BLINK HEALTH, INC. via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to market-based solutions to drug pricing, branded medication affordability, and patient access.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 National Defense Authorization Act (H.R.8800/S.4784).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
ALTRIA CLIENT SERVICES LLC via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to the regulation of tobacco products. Issues related to FDA illicit product enforcement.
Discussions related to FDA Tobacco and Cannabis Product Enforcement Policy.
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
ALKERMES, INC. via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Policiesimpacting pharmaceutical development, patient access, drug pricing, and supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALABAMA INSTITUTE FOR DEAF AND BLIND via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Education funding and labor issues related to the disabled; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BOEING COMPANY via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to reauthorization of the Toxic Substances Control Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
RESEARCH!AMERICA via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
General educationand support for federal funding of medical research.
Support for funding of research and policy issues related to indirect costs and accessibilityof grants and contracts. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Proposed Rule: Regulation for Federal Financial Assistance (Docket No. OMB-2026-0034; RIN 0348-AB88).
General education about the importance of support for federal funding of scientific research.
MERCK & CO., INC. via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
KIDNEY CARE PARTNERS via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Education about how to improve the quality of kidney care treatment, expand innovation, and other insurance/payment policies. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Education about how to improve the quality of kidney care treatment and expand innovation. Modernize Medicares payment system for end-stage renal disease (ESRD). Medicare coverage and reimbursement related to dialysis. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750). Improving Home Dialysis Act of 2026 (H.R.8875).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
BROAD INSTITUTE via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
General education about biomedical research and support for scientific funding. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. Education and awareness regarding genetic medicines for rare and ultra-rare diseases.
Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495). Education and discussion regarding Broad Institute capabilities and technologies relevant to national biological intelligence, biosurveillance, and reconnaissance (ISR).
VERTEX PHARMACEUTICALS INCORPORATED via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Policies impacting the manufacturing pharmaceutical products including tariffs.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
KLASKO IMMIGRATION LAW PARTNERS, LLP ON BEHALF OF INTEALTH via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties.
General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties. Education about the impact of J-1 visa interview pause and travel ban for foreign physicians. Issues related to the proposed rule regarding establishing a fixed time period of admission and an extension of stay procedure for nonimmigrant academic students, exchange visitors, and representatives of foreign information media.
EISAI, INC. via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · Q2
Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act (H.R.8800/S.4784); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); drug pricing.
KIDNEY CARE PARTNERS via CROSSROADS STRATEGIES, LLC
2026 · second_quarter · RR
Education about how to improve the quality of kidney care treatment and expand innovation. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
Education about how to improve the quality of kidney care treatment and expand innovation. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).
SQUARE 407 LP via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · 1T
Issues related to the rescissions package; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); FY2026 Continuing Appropriations and Extensions Act (H.R.5371/P.L.119-37).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROTON THERAPY CONSORTIUM via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Reimbursement issues related to proton therapy.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
RESEARCH!AMERICA via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
General educationand support for federal funding of medical research.
General education about the importance of support for federal funding of scientific research.
Support for funding of research and policy issues related to indirect costs and accessibilityof grants and contracts. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
BLINK HEALTH, INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to market-based solutions to drug pricing, branded medication affordability, and patient access.
Filing targets: Executive Office of the President (EOP)
GINKGO BIOWORKS, INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Education and outreach on automated lab technology; FY2027 National Defense Authorization Act.
Filing targets: Agriculture, Dept of (USDA), Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
APNIMED, INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to Medicare reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
MADRIGAL PHARMACEUTICALS, INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Issues related to CMMI Drug Pricing Demonstration Programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EPILEPSY FOUNDATION OF AMERICA via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Support affordable access to health insurance including through extension of Enhanced Advanced Premium Tax Credits.
Funding for epilepsy program research at CDC, NIH, DoD; S.494/H.R.1189, National Plan for Epilepsy Act; FY2027 Department of Defense Appropriations; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. Support coverage of and access to all epilepsy treatments. Support PBM reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
NATIONAL MULTIPLE SCLEROSIS SOCIETY via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Supporting extension of Enhanced Advanced Premium Tax Credits.
Supporting established funding levels for Medicare and Medicaid and protection of Medicaid's financing structure.
DoD funding-Congressionally Directed MS Research Program. NIH funding, FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. Ensuring access to care and coverage for people living with multiple sclerosis. Healthcare research, FY2027 Department of Defense Appropriations.
CENTERSTONE via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Issues and funding related to community mental health and substance use disorder.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Housing & Urban Development, Dept of (HUD), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
COCA-COLA BOTTLING COMPANY UNITED, INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Legislative and regulatory issues impacting the beverage industry, including beverage labeling.
Legislative and regulatory issues impacting the beverage industry, including SNAP in H.R.7567, Farm, Food, and National Security Act of 2026, and dietary guidelines. Issues related to the Make America Healthy Again Commission.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
BROAD INSTITUTE via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
General education about biomedical research and support for scientific funding. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments.
Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act and FY2027 Department of Defense Appropriations.
General education about biomedical research and support for scientific funding. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments.
KLASKO IMMIGRATION LAW PARTNERS, LLP ON BEHALF OF INTEALTH via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties. Education about the impact of J-1 visa interview pause and travel ban for foreign physicians. Issues related to the proposed rule regarding establishing a fixed time period of admission and an extension of stay procedure for nonimmigrant academic students, exchange visitors, and representatives of foreign information media.
General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties.
3M COMPANY via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
EPA/environmental regulations. Issues related to PFAS.
Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation, international tax and third-party litigation funding provisions.
Workforce, PPE, and industrial safety issues
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2027 National Defense Authorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
HALEON US HOLDINGS LLC via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Education about the importance of OTC products and benefits under Medicare Advantage.
Policies impacting access to over-the-counter products; FY2026 Financial Services and General Government Appropriations Act process (H.R.5166/S.3290); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75).
Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.
VERTEX PHARMACEUTICALS INCORPORATED via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine.
LIFESCIENCE LOGISTICS via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to pandemic preparedness and strategic stockpile readiness, including funding for state strategic stockpiles demonstration included in the PREVENT Act; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Issues related to pandemic preparedness and strategic stockpile readiness, including state strategic stockpiles demonstration included in the PREVENT Act. Pandemic and All- Hazards Preparedness Act reauthorization.
THE BOEING COMPANY via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to reauthorization of the Toxic Substances Control Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to tax reform; R&D tax credit; international taxation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations.
ALKERMES, INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Policiesimpacting pharmaceutical development, patient access, drug pricing, and supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Policies impacting the supply chain and manufacturing of medical devices and technology including tariffs. Issues related to reimbursement in Japan.
Policies impacting third party repair of medtech. Issues related to competitive bidding in the NDAA.
General education to advance policies that support innovation in the medical device industry. Issues related to the coverage and reimbursement of medical devices and technology, including AI. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
ALABAMA INSTITUTE FOR DEAF AND BLIND via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Education funding and labor issues related to the disabled; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARSH MCLENNAN via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to health care reform.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
EISAI, INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing.
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
TAKEDA PHARMACEUTICALS AMERICA, INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Issues related to tax reform; R&D tax credit; orphan drug tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
ALTRIA CLIENT SERVICES LLC via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · Q1
Discussions regarding the taxation of tobacco products.
Discussions related to FDA Tobacco and Cannabis Product Enforcement Policy.
Issues related to the regulation of tobacco products.
PROTON THERAPY CONSORTIUM via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · RR
Reimbursement issues related to proton therapy.
RESEARCH!AMERICA via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · RR
General education about biomedical research and support for scientific funding.
General education about biomedical research and support for scientific funding.
General education about biomedical research and support for scientific funding.
BLINK HEALTH, INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · RR
Issues related to market-based solutions to drug pricing, branded medication affordability, and patient access.
ALKERMES, INC. via CROSSROADS STRATEGIES, LLC
2026 · first_quarter · RA
Policiesimpacting pharmaceutical development, patient access, drug pricing, and supply chain.
AMERICAN ASSOCIATION OF COLLEGES OF OSTEOPATHIC MEDICINE via CROSSROADS STRATEGIES, LLC
2025 · fourth_quarter · 4A
Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885, Community TEAMS Act of 2025; FY2026 National Defense Authorization Act (S.2296/H.R.3838/P.L.119-60); FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); FY2026 Department of Defense Appropriations Act (H.R.4016/S.2572); H.R.1, One Big Beautiful Bill Act (P.L.119-21), higher education accountability provisions.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
BRISTOL-MYERS SQUIBB via CROSSROADS STRATEGIES, LLC
2025 · fourth_quarter · Q4
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Issues related to tax reform; R&D tax credit; international taxation.
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
MERCK & CO., INC. via CROSSROADS STRATEGIES, LLC
2025 · fourth_quarter · Q4
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838/P.L.119-60), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
TAKEDA PHARMACEUTICALS AMERICA, INC. via CROSSROADS STRATEGIES, LLC
2025 · fourth_quarter · Q4
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
GINKGO BIOWORKS, INC. via CROSSROADS STRATEGIES, LLC
2025 · fourth_quarter · Q4
Education and outreach on automated lab technology.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
APNIMED, INC. via CROSSROADS STRATEGIES, LLC
2025 · fourth_quarter · Q4
Issues related to Medicare reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
MADRIGAL PHARMACEUTICALS, INC. via CROSSROADS STRATEGIES, LLC
2025 · fourth_quarter · Q4
Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Issues related to CMMI Drug Pricing Demonstration Programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SQUARE 407 LP via CROSSROADS STRATEGIES, LLC
2025 · fourth_quarter · Q4
Issues related to the rescissions package; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); FY2026 Continuing Appropriations and Extensions Act (H.R.5371/P.L.119-37).
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to coverage of over-the-counter products with FSAs and HSAs.
Policies impacting access to over-the-counter products; FY2027 Financial Services and General Government Appropriations Act (H.R.8495).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); FY2027 Department of Homeland Security Appropriations Act (H.R.9310); FY2027 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.8845); FY2027 Financial Services and General Government Appropriations Act (H.R.8495); FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.9170); FY2027 National Security, Department of State, and Related Programs Appropriations Act (H.R.8595); provisions related to the regulation of tobacco products.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding implementation of medtech related provisions; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260).
General education to advance policies that support innovation in the medical device industry. Issues related to coverage and reimbursement of diagnostic tests, including issues related to FDA regulation of medical devices. Issues related to medical device sterilization. Policy issues related to the regulation of artificial intelligence for medical technology. Issues related to cybersecurity of medical devices manufactured in China. Policies that could impact supply chain for medical technology. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
Policies impacting the manufacturing pharmaceutical products including tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax reform; international taxation.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Issues related to tax reform; international taxation.
Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EPA/environmental regulations. Issues related to PFAS.
Filing targets: Defense Advanced Research Projects Agency (DARPA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, U.S. Trade Representative (USTR)
Discussions regarding implementation of medtech related provisions; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260).
General education to advance policies that support innovation in the medical device industry. Issues related to the coverage and reimbursement of medical devices and technology, including AI. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Policies impacting the supply chain and manufacturing of medical devices and technology including tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to tax reform; R&D tax credit; international taxation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to healthcare and payment for over-the-counter drugs; General education of over-the-counter switches, including reauthorization of the Over-the-Counter Monograph Drug User Fee Act and policies impacting a Nonprescription Drug Product with an Additional Condition for Nonprescription Use.
Issues related to coverage of over-the-counter products with FSAs and HSAs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); S.2658, Medication Affordability and Patent Integrity Act; S.3014, Ensuring Timely Access to Generics Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding the taxation of tobacco products.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to tax reform; R&D tax credit; orphan drug tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about biomedical research and support for scientific funding. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments.
General education about biomedical research and support for scientific funding. Transparency of federal funding for medical research dollars, including indirect costs. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. Support for the NIH All of Us Program. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495).
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Education about the impact of J-1 visa interview pause and travel ban impact for foreign physicians. Issues related to the proposed rule regarding establishing a fixed time period of admission and an extension of stay procedure for nonimmigrant academic students, exchange visitors, and representatives of foreign information media.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS)
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
General education about biomedical research and support for scientific funding. Transparency of federal funding for medical research dollars, including indirect costs. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75) and FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act and FY2027 Department of Defense Appropriations.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE
Education about the impact of J-1 visa interview pause and travel ban impact for foreign physicians. Issues related to the proposed rule regarding establishing a fixed time period of admission and an extension of stay procedure for nonimmigrant academic students, exchange visitors, and representatives of foreign information media.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS)
Issues related to healthcare and payment for over-the-counter drugs; General education of over-the-counter switches, including reauthorization of the Over-the-Counter Monograph Drug User Fee Act and policies impacting a Nonprescription Drug Product with an Additional Condition for Nonprescription Use.
Issues related to coverage of over-the-counter products with FSAs and HSAs.
Filing targets: Bureau of Industry and Security (BIS), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to medical countermeasure and supply management.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; issues related to COPD and Type One Diabetes (T1D).
Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding implementation of medtech related provisions for FY26 and FY27; H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
General education to advance policies that support innovation in the medical device industry. Issues related to coverage and reimbursement of diagnostic tests, including Issues related to FDA regulation of medical devices. Issues related to medical device sterilization. Policy issues related to the regulation of artificial intelligence for medical technology. Policies that could impact supply chain for medical technology. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
FY2026 Department of Homeland Security Appropriations Act (H.R.4213); FY2026 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.5342/S.2354); H.R.6938, Making consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-74); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2027 Department of Homeland Security Appropriations; FY2027 Commerce, Justice, Science, and Related Agencies Appropriations; FY2027 Financial Services and General Government Appropriations; FY2027 Transportation, Housing and Urban Development, and Related Agencies Appropriations; FY2027 National Security, Department of State, and Related Programs Appropriations; provisions related to the regulation of tobacco products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Issues related to tax reform; R&D tax credit; international taxation.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax reform; R&D tax credit; orphan drug tax credit; Section 899.
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE